아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

merck sharp and dohme limited - diflunisal - tablets - 125 milligram

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

merck sharp and dohme limited - diflunisal - tablets - 250 mg milligram

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

merck sharp and dohme limited - diflunisal - tablets - 375 milligram

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

merck sharp and dohme limited - diflunisal - tablets - 500 milligram

미국 - 영어 - NLM (National Library of Medicine)

h.j. harkins company, inc. - diclofenac potassium (unii: l4d5ua6cb4) (diclofenac - unii:144o8ql0l1) - diclofenac potassium 50 mg - carefully consider the potential benefits and risks of diclofenac potassium tablets and other treatment options before deciding to use diclofenac potassium tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). diclofenac potassium tablets are indicated: - for treatment of primary dysmenorrhea - for relief of mild to moderate pain - for relief of the signs and symptoms of osteoarthritis - for relief of the signs and symptoms of rheumatoid arthritis diclofenac potassium tablets are contraindicated in patients with known hypersensitivity to diclofenac. diclofenac potassium tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings , anaphylactic reactions and precautions , preexisting asthma ). diclofenac potassium tablets are contraindicate

미국 - 영어 - NLM (National Library of Medicine)

h.j. harkins company, inc. - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac tromethamine - unii:4eve5946bq) - ketorolac tromethamine 10 mg - carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac tromethamine. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. ketorolac tromethamine tablets are indicated for the short-term (≤ 5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. therapy should always be initiated with iv or im dosing of ketorolac tromethamine, and ketorolac tromethamine tablets are to be used only as continuation treatment, if necessary. the total combined duration of use of ketorolac tromethamine tablets and ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see warnings , precautions , dosage and administration , and adverse reactions ). patients should be switched to alternative analges

미국 - 영어 - NLM (National Library of Medicine)

h.j. harkins company, inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 500 mg - carefully consider the potential benefits and risks of naproxen delayed-release tablets and other treatment options before deciding to use naproxen delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). naproxen delayed-release tablets are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen as naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient’s weight. naproxen delayed-release tablets are not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products (see clinical pharmacology and dosage and administratio

미국 - 영어 - NLM (National Library of Medicine)

zydus pharmaceuticals (usa) inc. - diflunisal (unii: 7c546u4den) (diflunisal - unii:7c546u4den) - carefully consider the potential benefits and risks of diflunisal tablets and other treatment options before deciding to use diflunisal tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). diflunisal tablets are indicated for acute or long-term use for symptomatic treatment of the following: 1. mild to moderate pain 2. osteoarthritis 3. rheumatoid arthritis diflunisal tablets are contraindicated in patients with known hypersensitivity to diflunisal or the excipients (see description ). diflunisal tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic/analphylactoid reactions to nsaids have been reported in such patients (see warnings, anaphylactic/anaphylactoid reactions and precautions, preexisting asthma ). diflunisal tablets are contraindicated in the setting of coronary artery bypass graft (cabg) surger

미국 - 영어 - NLM (National Library of Medicine)

zydus lifesciences limited - diflunisal (unii: 7c546u4den) (diflunisal - unii:7c546u4den) - carefully consider the potential benefits and risks of diflunisal tablets and other treatment options before deciding to use diflunisal tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). diflunisal tablets are indicated for acute or long-term use for symptomatic treatment of the following: 1. mild to moderate pain 2. osteoarthritis 3. rheumatoid arthritis diflunisal tablets are contraindicated in patients with known hypersensitivity to diflunisal or the excipients (see description ). diflunisal tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic/analphylactoid reactions to nsaids have been reported in such patients (see warnings , anaphylactic/anaphylactoid reactions and precautions , preexisting asthma ). diflunisal tablets are contraindicated in the setting of coronary artery bypass graft (cabg) surg

미국 - 영어 - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - meloxicam (unii: vg2qf83cgl) (meloxicam - unii:vg2qf83cgl) - meloxicam 15 mg - meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis [see clinical studies (14.1)]. meloxicam tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis [see clinical studies (14.1)]. meloxicam tablets are contraindicated in patients with known hypersensitivity (e.g. anaphylactoid reactions and serious skin reactions) to meloxicam. meloxicam tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.13)]. meloxicam tablets are contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1)] . pregnancy category c; category d starting 30 weeks gestation. there are no adequate and well-controlled studies in pregnant women. meloxicam crosses the plac